BlogInsights Comparative effectiveness research in CMS drug price negotiation Allowable for the first time due to the Inflation Reduction Act, the Centers for Medicare…Richard ChumbleySeptember 12, 2024
BlogInsights Understanding payer perceptions of health inequalities in HTA and reimbursement decision-making The Evidence Base recently featured a 'deep dive' analysis of this ISPOR 2024 presentation. …Richard ChumbleyJune 6, 2024
BlogInsights Anticipating pricing and reimbursement for newly approved products prior to HTA decisions Tijana Ignjatovic, MA, PhD, Executive Director, Access & Pricing, applies the case study of Minjuvi…Richard ChumbleyMay 31, 2024
BlogInsights Parkinson’s progress: hopeful advances Andy Surinach, Executive Director of RWE and Data Strategy, delves into recent breakthroughs in Parkinson's…Richard ChumbleyApril 15, 2024
BlogInsights AMCP Nexus 2023: Healthcare stakeholders prepare for the Inflation Reduction Act (IRA) Medicare price negotiations AMCP Nexus 2023, held recently in Orlando, Florida, hosted a forum for healthcare stakeholders to…Richard ChumbleyNovember 2, 2023
Blog Considerations for the use of RWD and RWE to support regulatory decision-making for drug and biological products Alexandra Sosinsky, our Director, Pharmacoepidemiology & Safety, offers her thoughts on FDA’s recent guidance regarding…Richard ChumbleyOctober 11, 2023
Blog Shining a light on rare disease: evidence challenges and solutions Catherine Tak Piech argues that specialists and a plethora of new technologies are now well…Casey FrushourJanuary 19, 2022